Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Abortion, Habitual D000026 5 associated lipids
Acidosis D000138 13 associated lipids
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Airway Obstruction D000402 13 associated lipids
Albuminuria D000419 18 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia D000740 21 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Ushiyama S et al. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. 1988 Thromb. Res. pmid:3175990
Tsuboi T et al. Effect of gliclazide on prostaglandin and thromboxane synthesis in guinea-pig platelets. 1981 Jan 1-15 Thromb. Res. pmid:7233394
Rostagno C et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. 1991 Thromb. Res. pmid:1754998
Catella F and FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. 1987 Thromb. Res. pmid:3686481
Weide I et al. Effects of cyclooxygenase inhibitors on ex vivo cysteinyl-leukotriene production by whole human blood allowed to clot spontaneously. Comparison to stimulated blood. 1992 Thromb. Res. pmid:1440511
Winther K et al. Platelet function and fibrinolytic activity in cervical spinal cord injured patients. 1992 Thromb. Res. pmid:1321515
Tanoue K et al. A new variant of thrombasthenia with abnormally glycosylated GP IIb/IIIa. 1987 Thromb. Res. pmid:3629560
Davì G et al. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. 1985 Thromb. Res. pmid:2933846
Voss R et al. In vitro and ex vivo effects of aspirin in patients on a low-dose aspirin therapy. 1993 Thromb. Res. pmid:8122187
Takasaki W et al. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2. 1991 Thromb. Res. pmid:1957275
Riess H et al. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients. 1986 Thromb. Res. pmid:3012819
Altman R et al. Synergistic actions of PAF-acether and sodium arachidonate in human platelet aggregation. 1. Studies in normal human platelet rich plasma. 1986 Thromb. Res. pmid:3014677
Alessandrini P et al. Physiologic variables affecting thromboxane B2 production in human whole blood. 1985 Thromb. Res. pmid:3983893
Grignani G et al. Activation of platelet prostaglandin biosynthesis pathway during neoplastic cell-induced platelet aggregation. 1984 Thromb. Res. pmid:6729776
Best LC et al. The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. 1980 Thromb. Haemost. pmid:6773171
Han P et al. Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide. 1982 Thromb. Haemost. pmid:7101234
Greer IA et al. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation. 1985 Thromb. Haemost. pmid:2867620
Miller KW and Keith JC Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension. 1988 Thromb. Haemost. pmid:3238644
Teng CM et al. ADP-mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb. 1997 Thromb. Haemost. pmid:9066010
Santilli F et al. Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis. 2013 Thromb. Haemost. pmid:24030807
Joseph S et al. Effect of the polyamine-spermine on agonist-induced human platelet activation--specific inhibition of "aggregation-independent" events induced by thrombin, but not by collagen, thromboxane mimetic, phorbol ester or calcium ionophore. 1987 Thromb. Haemost. pmid:3110996
di Minno G et al. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. 1981 Thromb. Haemost. pmid:6266066
Swartz SL and Moore TJ Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. 1990 Thromb. Haemost. pmid:2339363
Watanabe J et al. Effect of vitamin E on platelet aggregation in diabetes mellitus. 1984 Thromb. Haemost. pmid:6495252
Matsumoto M et al. Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. 1980 Thromb. Haemost. pmid:7423441
Carter AJ et al. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. 1984 Thromb. Haemost. pmid:6377567
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Honey AC et al. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. 1986 Thromb. Haemost. pmid:3775692
Kyrle PA et al. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man--effect of low-dose aspirin. 1987 Thromb. Haemost. pmid:2954260
Gresele P et al. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. 1990 Thromb. Haemost. pmid:2274931
Krishnamurthi S et al. Effect of pyridoxal 5'-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation--role of Schiff base formation. 1982 Thromb. Haemost. pmid:6891107
Martinuzzo ME et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. 1993 Thromb. Haemost. pmid:8115993
Larson MK et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. 2008 Thromb. Haemost. pmid:18841286
Scharf RE In vitro thromboxane synthesis of depleted blood platelets following renal transplantation. 1990 Thromb. Haemost. pmid:2148845
Hoet B et al. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. 1990 Thromb. Haemost. pmid:2148849
Cattaneo M et al. Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium. 1985 Thromb. Haemost. pmid:3927505
Wang WJ and Huang TF A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist. 2001 Thromb. Haemost. pmid:11686327
Jackson C et al. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect. 1989 Thromb. Haemost. pmid:2546286
Davì G et al. Increased thromboxane metabolites excretion in liver cirrhosis. 1998 Thromb. Haemost. pmid:9569186
Sheu JR et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. 2000 Thromb. Haemost. pmid:10823277
Crescente M et al. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. 2007 Thromb. Haemost. pmid:17549313
Undas A et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. 2007 Thromb. Haemost. pmid:17549314
Homoncik M et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. 2000 Thromb. Haemost. pmid:10739392
Perneby C et al. Dose- and time-dependent antiplatelet effects of aspirin. 2006 Thromb. Haemost. pmid:16601836
Eldor A et al. Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. 1983 Thromb. Haemost. pmid:6346571
Menys VC and Davies JA Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. 1983 Thromb. Haemost. pmid:6346575
Hampton KK et al. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. 1990 Thromb. Haemost. pmid:2073296
Vejar M et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. 1990 Thromb. Haemost. pmid:2363117
Foo LC et al. Platelets of habitual smokers have reduced susceptibility to aggregating agent. 1991 Thromb. Haemost. pmid:2048056
Dragani A et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. 2012 Thromb. Haemost. pmid:22782530
Gordge MP et al. Platelet function and the bleeding time in progressive renal failure. 1988 Thromb. Haemost. pmid:3187950
Vezza R et al. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. 1997 Thromb. Haemost. pmid:9408024
Greer IA et al. Platelet activation in allergic asthma. 1985 Thromb. Haemost. pmid:2931855
Hohlfeld T et al. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. 1994 Thromb. Haemost. pmid:7513092
Han P et al. Verapamil and collagen-induced platelet reactions--evidence for a role for intracellular calcium in platelet activation. 1983 Thromb. Haemost. pmid:6415847
Turpeinen AM et al. Replacement of dietary saturated by unsaturated fatty acids: effects of platelet protein kinase C activity, urinary content of 2,3-dinor-TXB2 and in vitro platelet aggregation in healthy man. 1998 Thromb. Haemost. pmid:9798986
Guthikonda S et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. 2008 Thromb. Haemost. pmid:18612542
Gresele P et al. Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 1997 Thromb. Haemost. pmid:9423790
Naesh O et al. Platelet function in surgical stress. 1985 Thromb. Haemost. pmid:2935969
Davì G et al. The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects. 1983 Thromb. Haemost. pmid:6417815
Dale J et al. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. 1983 Thromb. Haemost. pmid:6689091
Hornby EJ et al. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. 1989 Thromb. Haemost. pmid:2529661
Bar J et al. The regulation of platelet aggregation in vitro by interleukin-1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. 1997 Thromb. Haemost. pmid:9364994
Husted SE et al. Intravenous acetylsalicylic acid--dose-related effects on platelet function and fibrinolysis in healthy males. 1992 Thromb. Haemost. pmid:1412171
Wang JS et al. Effect of strenuous arm exercise on oxidized-LDL-potentiated platelet activation in individuals with spinal cord injury. 2000 Thromb. Haemost. pmid:10928481
Subbiah MT et al. Studies of aggregation and thromboxane B2 synthesis in avian thrombocytes: comparison between atherosclerosis-susceptible and resistant breeds. 1980 Thromb. Haemost. pmid:7455983
Zahavi M et al. Abnormal typical pattern of platelet function and thromboxane generation in unstable angina. 1989 Thromb. Haemost. pmid:2531938
Barrett PA and Butler KD Shortening of platelet survival by induced hypercholesterolaemia in rabbits and its prolongation by anagrelide. 1983 Thromb. Haemost. pmid:6648889
Connellan JM et al. Investigation of alternative mechanisms of collagen-induced platelet activation by using monoclonal antibodies to glycoprotein IIb-IIIa and fibrinogen. 1986 Thromb. Haemost. pmid:2940722
Szczeklik A et al. Prolonged bleeding time, reduced platelet aggregation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma and hay fever. 1986 Thromb. Haemost. pmid:3563961
Falcon CR et al. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium. 1993 Thromb. Haemost. pmid:8259535
Fruzzetti F et al. Platelet-vessel wall interactions with third-generation oral contraceptives: no evidence of detrimental effects. 1999 Thromb. Haemost. pmid:10494782
Cattaneo M et al. Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 1988 Thromb. Haemost. pmid:3146144
Fimognari FL et al. Nocturnal rise of urinary thromboxane B 2 in patients with coronary artery disease. 2005 Thromb. Haemost. pmid:15735822
De Caterina R et al. Organic nitrates: direct antiplatelet effects and synergism with prostacyclin. Antiplatelet effects of organic nitrates. 1988 Thromb. Haemost. pmid:3291182
Teng CM and Ko FN Comparison of the platelet aggregation induced by three thrombin-like enzymes of snake venoms and thrombin. 1988 Thromb. Haemost. pmid:3291184
de Castellarnau C et al. Prostacyclin and thromboxane production by autogenous femoral veins grafted into the arterial circulation of the dog. 1989 Thromb. Haemost. pmid:2665174
Davì G et al. Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. 1995 Thromb. Haemost. pmid:8584998
Habib A et al. Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. 1995 Thromb. Haemost. pmid:8585020
Zahavi J and Zahavi M Enhanced platelet release reaction, shortened platelet survival time and increased platelet aggregation and plasma thromboxane B2 in chronic obstructive arterial disease. 1985 Thromb. Haemost. pmid:3158092
Etulain J et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. 2012 Thromb. Haemost. pmid:22159527
Rocca B et al. Increased thromboxane biosynthesis in essential thrombocythemia. 1995 Thromb. Haemost. pmid:8607099
Korbut R et al. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors. 1987 Thromb. Haemost. pmid:3324381
Véricel E et al. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients. 2015 Thromb. Haemost. pmid:25832443
Kyrle PA et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. 1988 Thromb. Haemost. pmid:2975407
Spowart K et al. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. 1988 Thromb. Haemost. pmid:3266379
Cerletti C et al. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma". 1985 Thromb. Haemost. pmid:4049312
Hillbom M et al. Platelet thromboxane formation and bleeding time is influenced by ethanol withdrawal but not by cigarette smoking. 1985 Thromb. Haemost. pmid:4049313
Aoki T et al. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis. 1998 Thromb. Haemost. pmid:9657446
McMahon GS et al. Transient heparin-induced platelet activation linked to generation of platelet 12-lipoxygenase. Findings from a randomised controlled trial. 2013 Thromb. Haemost. pmid:23494053
Larsen SB et al. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. 2013 Thromb. Haemost. pmid:23407706
Dotevall A et al. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. 1992 Thromb. Haemost. pmid:1455405
de Boer A et al. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. 1991 Thromb. Haemost. pmid:1722918
De Caterina R et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. 1985 Thromb. Haemost. pmid:4082090
Davì G et al. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. 1996 Thromb. Haemost. pmid:8819248
Ding YA et al. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. 1985 Thromb. Haemost. pmid:4089801
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Carter AJ and Hanley SP The effect of platelet number and haematocrit on whole blood thromboxane synthesis. 1985 Thromb. Haemost. pmid:4024033
Brox JH et al. The effect of cod liver oil and corn oil on platelets and vessel wall in man. 1981 Thromb. Haemost. pmid:7031981
Strano A et al. Thromboxane formation by platelets and platelet sensitivity to prostacyclin in patients with acute myocardial infarction. 1981 Thromb. Haemost. pmid:7036402